Biotech

All Articles

Bicara, Zenas look for IPOs to drive late-phase resources towards market

.Bicara Therapies and also Zenas Biopharma have supplied fresh motivation to the IPO market with fil...

Genentech to finalize cancer cells immunology research team

.Genentech is going to close its cancer immunology study division, and also unit head and renowned t...

Kezar loses strong lump but to show its own well worth in stage 1 test

.Kezar Life Sciences is dropping its dim phase 1 solid growth medicine as the biotech goes all-in on...

Acelyrin falls izokibep, dismisses 3rd of personnel

.Even with izokibep preserving its newfound winning streak in the center, Acelyrin is no longer focu...

Rivus' phase 2 obesity-related heart failure test reaches endpoint

.Rivus Pharmaceuticals has plumped up the potential customers of its own fat-busting, muscle-sparing...

Ovid standstills preclinical job, IV system after soticlestat fail

.Ovid Therapeutics presently uncovered final month that it was trimming its headcount as the busines...

Eli Lilly opens $700M nucleic acid R&ampD facility in Boston Port

.Eli Lilly has opened up a $700 thousand R&ampD center in the Boston Port, enhancing its RNA and DNA...

Boundless Bio creates 'modest' layoffs 5 months after $100M IPO

.Simply five months after protecting a $100 thousand IPO, Limitless Bio is currently laying off some...

Halda's $126M will evolve 'keep and kill' cyst medications

.The initial phases of oncology R&ampD may not be short of appealing brand-new modalities, as well a...

Lykos 'regrets' not revealing study violations along with publisher

.Psychopharmacology has taken 3 write-ups about midstage professional test records analyzing Lykos T...